The Wolverine stack, meaning the repair peptides BPC-157 and TB-500 run together, has been tested against its own parts exactly once: 32 rats with a surgically cut and repaired Achilles tendon, four groups of eight, dosed for four weeks, reported by Bicer and colleagues in Joint Diseases and Related Surgery in 2026. The combination did not beat either compound used on its own, and the group with the clearest advantage on tendon strength was TB-500 alone, the compound most stacking guides treat as the optional add-on rather than the main event. That is one study, in rats, at one dose of each, over four weeks, so it is not proof that no added benefit exists in people; it is the entire head-to-head record.
The case for running BPC-157 and TB-500 together was a mechanism story for a decade, and in July 2026 it was tested. Bicer and colleagues cut and surgically repaired the Achilles tendon in 32 rats, split them into four groups of eight (no treatment, BPC-157 alone, TB-500 alone, both together), treated them for four weeks, and reported that the pair did not beat either compound used on its own 1. The arm with the clearest advantage on tendon strength was TB-500, the compound most stacking guides file as the optional add-on that works body-wide rather than as the main event.
What is the Wolverine stack?
The Wolverine stack is BPC-157 and TB-500 taken together, named after the comic character who heals fast. BPC-157 is a synthetic chain based on a protein found in stomach fluid, and most of its research is about connective tissue and the gut lining (that gut work is a separate story, covered on our gut healing page and the gut evidence ranking). TB-500 is a lab-made copy of the active fragment of thymosin beta-4, a protein your body already makes that helps cells travel to the site of an injury. Neither is an approved medicine, no clinician designed the pairing, and no researcher named it. If peptides are new to you, the beginners' guide and stacking 101 cover the ground this page assumes.
The stack's origin, its member profiles, the reasoning people give for pairing them and the provenance of the doses you see quoted all live on the Wolverine stack profile. That page's finding about where those numbers came from frames everything below.
Every page quoting a dose for this stack quotes it without a source, and they do not agree with each other. The trail for the twice-weekly TB-500 schedule leads to a 2011 product insert for horses, and to a bodybuilding forum.
Is the Wolverine stack proven to work?
No. The pairing has one head-to-head experiment behind it and the experiment did not support it. Bicer and colleagues transected and repaired the Achilles tendon in 32 male Sprague-Dawley rats, 12 weeks old and around 330 g, then randomised them into four groups of eight 1. Every treatment was intraperitoneal, meaning injected into the abdominal cavity rather than near the tendon, and ran for four weeks after surgery. Two things were measured at the end: maximum load to failure, which is how much pull the repaired tendon took before it came apart, and two microscope scoring systems for tendon tissue quality, the Movin score and the Bonar score, where a lower score means tissue that looks closer to healthy tendon.
| Group (8 rats each) | What it received for 4 weeks | Tendon strength (maximum load to failure) | Tissue quality under the microscope |
|---|---|---|---|
| Control | Surgery and repair, no peptide | Baseline | Baseline |
| BPC-157 alone | 10 mcg/kg/day into the abdominal cavity | Higher than control, but the difference did not reach statistical significance | Numerically better, with no significant difference on total scores |
| TB-500 alone | 60 mcg/kg/day into the abdominal cavity | Higher than control and statistically significant (p < 0.05) | Significantly better than control on both systems (Bonar p = 0.016, Movin p = 0.017) |
| Both combined | Both of the above, at the same doses | No advantage over either compound given alone | Significantly better than control on the Movin score (p = 0.040), with no advantage over either compound alone |
Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.
Read the combination row carefully, because the sloppy version of this result is already circulating. Rats given both compounds did better than untreated rats on tendon architecture, on one of the two scoring systems. The claim the study supports is that the combination beat doing nothing and did not beat either compound on its own 1. One limit sits on the TB-500 result too: the paper describes that arm as synthetic thymosin beta-4, which does not make clear whether the seven-amino-acid fragment sold in a vial as TB-500 or the full-length protein was dosed 1. The authors offer one possible reason for the missing addition, and flag it as unconfirmed: the absence of additive effects may reflect convergence on shared downstream pathways, meaning both compounds may push the same repair machinery rather than two separate ones, a hypothesis they say requires further experimental confirmation.
Does adding TB-500 to BPC-157 do anything?
In the one experiment that asked, adding TB-500 to BPC-157 did not improve on BPC-157 by itself, and adding BPC-157 to TB-500 did not improve on TB-500 by itself 1. That inverts the usual ordering, in which BPC-157 is the primary compound and TB-500 is the optional extra. Neither result has been reproduced, in rats or anywhere else, and no study of any kind has compared the two in a human tendon.
BPC-157 alone or TB-500 alone, on the evidence that exists
Why people pair them anyway, and what that argument is worth
The reasoning on the clinic pages we reviewed for the stack profile is that the two compounds work at different scales, so they cover different halves of the same problem. It is a satisfying explanation, and it is the entire case for the pairing.
The complementary-mechanism argument, step by step
There is a second problem with the tidy version, and it is about where the drug goes. As our Wolverine stack profile documents, the BPC-157 animal results people cite for local action were produced by dosing into the abdomen or into the drinking water, nowhere near the injury, and nothing published shows that injecting it near an injury does more than injecting it anywhere else. The head-to-head study above followed the same pattern: every dose went into the abdominal cavity 1. For how BPC-157 is thought to work at the tissue level, see how BPC-157 works, and for where both compounds sit against everything else used for soft-tissue repair, see the evidence ranking for healing peptides.
What changed in 2026
Four dated things get quoted at this pairing, three of them from 2026. Only one changes what is known about whether the pairing works; the rest change the paperwork or the mechanism story, and what they change for a reader is mostly nothing yet.
| Date | What happened | What it changes for you |
|---|---|---|
| 15 April 2026 | Section 503A is the rule that lets a compounding pharmacy mix a drug for one named patient, and its bulks list names which raw ingredients they are allowed to use. The FDA announced that seven peptides, among them BPC-157, TB-500, KPV and MOTS-c, would come off the 503A Category 2 list after seven calendar days, because the nominations behind their listing had been withdrawn. A Federal Register notice the next day announced a public meeting for July on whether those same seven should be added to the bulks list 7. | Nothing about safety or effectiveness. The analysis this traces to is explicit that removing a substance from Category 2 does not on its own authorise using it in compounding, and neither compound was added to the list that authorises compounding pharmacies to make it 7. |
| 23 July 2026 | The Pharmacy Compounding Advisory Committee voted to recommend BPC-157 (8 to 6, 1 abstention), KPV (8 to 6, 1 abstention), TB-500 (8 to 6, 1 abstention) and MOTS-c (7 to 5, 2 abstentions) for the 503A bulks list. The committee does not make law and does not issue approvals; the FDA can accept, reject or sit on the recommendation 8. | Nothing is authorised today that was not authorised on 22 July. Neither compound is on the bulks list and neither is an approved medicine. The full picture is on our 2026 US legal breakdown. |
| 23 July 2026 | Bicer and colleagues published the only head-to-head test of the pairing, in 32 rats with surgically repaired Achilles tendons 1. | This is the one that matters. The pairing's central claim was tested and the extra benefit did not appear. |
| March 2024, still being quoted | A doping-control laboratory published an analytical method paper for detecting TB-500 and its breakdown products, and screened those products for wound-healing activity in cultured skin cells 3. | A hypothesis about which molecule does the work, measured in a dish. It says nothing yet about a tendon, an animal or a person. |
The metabolite screen, described accurately
TB-500 is itself Ac-LKKTETQ, an acetylated fragment of thymosin beta-4. Rahaman and colleagues built a laboratory method to measure it and its metabolites, meaning the shorter fragments left after the body breaks it down, then ran those fragments through a scratch assay, which is cultured skin cells in a dish with a gap scraped through them to see which treatment closes the gap fastest. Only the shorter fragment Ac-LKKTE produced significant activity against control, and the authors reported no toxicity in those cultured cells for the parent compound or its metabolites 3. That is an observation in a dish about cell survival; it is not a safety finding in an animal or a person, and no clinical safety data exists for either compound 2. Quote their conclusion exactly, because a paraphrase of it that adds the word prodrug has been circulating and that word never appears in the paper.
Our results also suggest that the previously reported wound-healing activity of TB-500 in literature may be due to its metabolite Ac-LKKTE rather than the parent form.Rahaman KA, Muresan AR, Min H, et al., Journal of Chromatography B, 2024 [[3]]
That is a suggestion from cells in a dish in a method-development paper. One cell-culture screen does not change how a compound should be given, stored or scheduled, and nobody has followed it up in an animal or a person.
Who wrote the BPC-157 literature
A Polish research team counted the roughly 200 BPC-157 studies listed on PubMed and found that the vast majority include Predrag Sikiric or his colleague Sven Seiwerth as a main author, which they argued could lead to confirmation bias 11. That is not an accusation of fraud and it does not make the findings wrong. It does mean that when you read that BPC-157 has hundreds of studies behind it, you are mostly reading one laboratory, and the head-to-head above is notable partly because it came from somewhere else.
Can you mix BPC-157 and TB-500 in the same syringe?
Nobody knows, because no published study has tested BPC-157 and TB-500 mixed together in one syringe. Every answer you will find on a forum or a clinic page is inference from the fact that both are water-soluble peptides, not a compatibility finding, and no stability data exists for the two in a shared solution. Any page that tells you flatly that mixing is fine has no source for it, including the earlier version of this page, which said so and was wrong to. Handling, reconstitution and storage are covered on our reconstitution guide and the injection hygiene guide, which own that material.
Should you add a third peptide such as GHK-Cu?
Nothing has been published on the three-way version at all. Adding a third compound to a pair that has never beaten its own parts multiplies the cost, the injections and the unknowns. GHK-Cu is a real compound with real research, most of it in skin and wound models rather than tendon; read it on its own terms at the GHK-Cu monograph and how GHK-Cu works, not as an upgrade to a stack. The claim that experienced users have converged on a three-peptide version has no count, no survey and no source behind it, and community consensus is not a tier of evidence. For the general principles of putting compounds together, how to build a peptide stack covers them.
Why did the Wolverine stack do nothing for me?
Start with the ordinary explanations, in this order, and get to genetics last, because the ordinary ones are far more likely and several of them are checkable.
- What was in the vial. Research-chemical vials are not made to pharmaceutical standards, and purity and endotoxin, meaning bacterial residue that triggers fever and inflammation, are the first thing to suspect when nothing happens at all 5.
- The injury is not the injury you assumed. A partial tear, a full rupture and a nerve problem can produce a similar ache from the outside, and a full rupture is a surgical question. Imaging answers this and a peptide does not.
- Time and load. The rat study measured at four weeks after surgery 1, while human tendon remodelling runs on a scale of months, and progressive loading rehabilitation is the mainstay of tendon management. It has human evidence behind it; neither of these compounds does 24. Condition context sits on our tendonitis page and the injury recovery page, and how long to run something, plus the ordinary errors that make nothing happen, are covered on the cycling guide and common dosing mistakes.
- Expectations built on numbers nobody measured. No study in any species has measured a non-response rate for this pairing, so any percentage you have seen for how often it fails was invented.
- The compounds may not do in people what the marketing says. The whole human record for BPC-157 that a 2025 systematic review, meaning a search of the published literature under fixed rules, could find after screening 544 articles from 1993 to June 2024 was one retrospective report: 12 people given an injection into the knee joint for chronic knee pain, 7 of whom reported relief lasting more than six months 2. The review found no clinical safety data at all. Condition context for knee pain sits on our joint pain page.
- Only after all of the above, your genetics, which is covered further down and has less to say here than most pages pretend.
How do you know what is in the vial?
This is the largest practical risk on the page, and it is larger than the question of whether the pairing works. Mendias and Awan's 2026 review in Sports Medicine covers the grey market these compounds are bought through, including purity, contamination, placebo response and the way social media amplifies single anecdotes 5. A larger sample analysis was posted in April 2026 as a preprint, meaning a paper that has not been peer reviewed: across 6,441 samples of 14 peptides including BPC-157 and TB-500, between 41.6 and 71.1 percent failed basic quality criteria depending on which of two quality acceptance models was applied, and in a 243-sample subset tested for endotoxin, 15 percent carried measurable levels. Treat those figures as preliminary until they clear peer review, and treat the direction they point in as consistent with the peer-reviewed review above 5, which is the citation to lean on. Our evidence ranking for healing peptides carries the fuller treatment of that dataset.
Affiliate disclosure: our vendor comparison carries affiliate links, and we earn a commission if you buy through them. That is why this section comes before the link. Third-party purity testing on the specific lot is the only thing that answers the question for the vial in your hand, and no vendor page substitutes for it.
What your genes can and cannot tell you about this pairing
No trial in any species has sorted responders from non-responders by genotype for BPC-157 or for TB-500. That sentence is the whole state of the field, and any page offering to predict your response to either compound from a DNA file is making it up, including earlier versions of this one.
The figure people reach for instead comes from injury risk rather than peptide response. Leznicka and colleagues genotyped 114 physically active Polish students, 53 of whom had been injured and 61 of whom had not, and reported that carriers of one copy each of the two versions of the collagen variant COL1A1 rs1800012 had 2.2 times the odds of injury compared with people carrying two identical copies, adjusted for age and sex 6. The confidence interval, meaning the range the study can say the true effect plausibly falls in, ran from 0.59 to 5.07. That range includes 1, the value meaning no effect at all, so the study cannot rule out that the variant makes no difference. A study of 114 students measures who gets hurt. It cannot support a protocol.
For this pairing, a genotype changes nothing you would do. That is more useful than a genotype table implying otherwise.
Safety, legality and sport testing
On the human record: the systematic review of BPC-157 in orthopaedic sports medicine found no clinical safety data at all 2, and the 2026 narrative review written for orthopaedic and sports medicine physicians put its conclusion plainly 4.
information regarding the indications, dosing, frequency, and duration of treatment remains unknownMayfield CK, Bolia IK, Feingold CL, et al., American Journal of Sports Medicine, 2026 [[4]]
On adverse experiences: STAT, in a piece by Sara Talpos published on 3 February 2026, collected accounts from people who had taken BPC-157, including an itch that spread over one person's entire body, intense anxiety that one user described in the words "It felt like someone was grabbing my chest and squeezing it", hallucinations on closing the eyes, and anhedonia, meaning an inability to feel pleasure or joy 11. The piece hedges those accounts itself, reporting that as with the claimed benefits of the peptide, it is hard to establish what link, if any, exists between BPC-157 and these experiences. They are user reports rather than trial data, and the absence of trial data is the reason they are the best safety signal available.
On sport: BPC-157 is prohibited under the S0 non-approved substances category 9, and thymosin beta-4 and its derivatives, with TB-500 named as the example, were added as prohibited growth factors under S2.3 on the 2018 list 10. On the Prohibited List both of those categories sit under the heading for substances prohibited at all times, in and out of competition. A tested athlete taking either is risking a ban.
On legality: neither compound is on the 503A bulks list and neither is an approved medicine, whatever the April and July 2026 news implied 78. Our 2026 US legal guide carries the full breakdown, and the muscle recovery ranking covers the wider repair category.
If you are hurt and someone has told you to run both, the thing to take away is that the pairing's promise of being more than the sum of its parts has been checked once and did not hold, in rats, at one dose of each, over four weeks. Get the injury diagnosed by a clinician who can image it, follow the loading programme they set, and read anything about the stack, this page included, as an account of thin evidence rather than as a protocol.
Nothing in a DNA file can tell you whether this pairing will work for you. No trial in any species has tested that, and this page says so above. What our report does cover is the rest of the picture: all 39 peptides we score, ranked against the markers you actually carry, and 8 pharmacogenes that affect how you clear the ordinary medicines sitting alongside a rehabilitation plan. Educational only, not medical advice, and reviewed by a human before it reaches you.
Get your DNA report- The pairing has now been tested against its own parts, and the extra part did not show up
The guides that sell the Wolverine stack sell a mechanism story: BPC-157 builds the blood supply, TB-500 moves the repair cells, so together they cover both halves of tendon healing. In July 2026 that story was tested directly for the first time, in 32 rats with a cut and repaired Achilles tendon. The combination beat doing nothing, but it did not beat either compound used alone, and the single arm with a statistically significant strength advantage was TB-500 by itself [[1]].
- One null result is not proof of no effect, and both halves of that belong in the same sentence
A study of 32 rats, at one dose of each compound, over four weeks, cannot rule out an added benefit at a different dose, over a longer period, or in a human tendon that wore out slowly instead of being cut with a scalpel [[1]]. The correct reading is that the pairing's reputation rests on a mechanism argument plus one experiment that failed to find the thing the argument predicts.
- The 2026 regulatory news changes only the paperwork
BPC-157 and TB-500 came off the FDA's Category 2 compounding list in April 2026 because the nominations behind that listing were withdrawn, and removing a substance from Category 2 does not by itself authorise compounding with it [[7]]. An advisory committee then recommended both for the compounding bulks list in July 2026 by a vote of 8 to 6 [[8]]. Neither event is an approval, neither committee vote is binding on the FDA, and nothing about what has been demonstrated in a tendon changed on either date.
Sources11
- Bicer O, Adanir O, Guleryuz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Dis Relat Surg. 2026;37(3):822-837.
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495.
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024;1235:124033.
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229.
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935.
- Leznicka K, Zyzniewska-Banaszak E, Gebska M, et al. Interactions between Gene Variants within the COL1A1 and COL5A1 Genes and Musculoskeletal Injuries in Physically Active Caucasian. Genes (Basel). 2021;12(7):1056.
- Landmon CA, Davies C, Pape SM, Bassett SE, McCann JD (Polsinelli PC). Tiny Chains, Big Changes? What FDA's Latest Actions Mean for Peptide Compounding. National Law Review, 22 April 2026. Covers the 15 April 2026 removal of seven peptides from 503A Category 2 and the 16 April 2026 Federal Register notice announcing the July public meeting.
- Ravitz JR, Gadiock PS, Lee JH, et al. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. McDermott Will & Emery, 27 July 2026.
- USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. Accessed 19 September 2026.
- USADA. 2018 Prohibited List: Summary of Major Changes. Accessed 19 September 2026.
- Talpos S. From Croatia to MAHA: How an unapproved drug became the next hot peptide. STAT, 3 February 2026 (co-published with Undark).
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
Frequently asked questions
Is the Wolverine stack proven to work?
No. The pairing of BPC-157 and TB-500 has one head-to-head experiment behind it: 32 rats with surgically cut and repaired Achilles tendons, four groups of eight, four weeks of treatment into the abdominal cavity, published by Bicer and colleagues in 2026. The combination beat no treatment on one of the two tendon tissue scoring systems but did not beat either compound used alone, and only TB-500 alone reached statistical significance on tendon strength [[1]]. There is no human trial of the pairing and no human tendon trial of either compound.
Is the Wolverine stack legal in the US in 2026?
Neither BPC-157 nor TB-500 is an approved medicine, and neither is on the 503A bulks list that names the raw ingredients a compounding pharmacy is allowed to use. The FDA announced on 15 April 2026 that seven peptides including both of them would come off the Category 2 compounding list, because the nominations behind that listing had been withdrawn rather than because the FDA made a new finding about them, and removal from Category 2 does not on its own authorise compounding [[7]]. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend each of them for the bulks list, and that vote is a recommendation the FDA can accept, reject or leave alone [[8]]. Both are sold as research chemicals and both are prohibited in tested sport [[9]][[10]].
Does adding TB-500 to BPC-157 do anything?
In the only experiment that asked, no. Bicer and colleagues compared BPC-157 alone, TB-500 alone and the two together in rats with surgically cut and repaired Achilles tendons. Adding TB-500 to BPC-157 did not improve on BPC-157 by itself, adding BPC-157 to TB-500 did not improve on TB-500 by itself, and the only arm with a statistically significant gain in tendon strength was TB-500 alone [[1]]. That result has not been reproduced anywhere, and no study of any kind has compared the two in a human tendon.
Can you mix BPC-157 and TB-500 in the same syringe?
No published study has tested BPC-157 and TB-500 mixed together in one syringe, and no stability or compatibility data exists for the two in a shared solution. Every answer circulating online is inference from the fact that both are water-soluble peptides. Reconstitution, storage and handling are covered on the PeptidesDNA reconstitution guide and injection hygiene guide.
Why did the Wolverine stack do nothing for me?
Nobody has measured a non-response rate for this pairing in any species, so any percentage you have seen quoted is invented. The likely explanations, in order, are what the vial contained, since grey-market purity and contamination are documented problems [[5]], an injury that is not the injury you assumed and needs imaging, insufficient time and progressive loading rehabilitation, and the possibility that the compounds do not do in people what the marketing says [[2]]. Genetics comes last, because no trial in any species has sorted responders from non-responders by genotype for either compound.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.